TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY

• US 20090274626A1
• Filed: 01/29/2008
• Published: 11/05/2009
• Est. Priority Date: 07/29/2005
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Kenny, Paraic A., Bissell, Mina J.
• Application Number:
  US12/022,049
• Publication Number:
  US 20090274626A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: C07K 14/485 Epidermal growth factor [EGF], i.e. urogastrone
• CPC Class Codes: C07K 14/495 Transforming growth factor [TGF]
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 9/6489 Metalloendopeptidases (3.4.24)
• CPC Class Codes: C12Y 304/24086 ADAM 17 endopeptidase (3.4.24.86), i.e. TNF-alpha converting enyzme

Abstract

The invention provides methods for modulating tumor cell proliferation by contacting cells (e.g. tumor cells) with a TACE inhibitor and a compound that inhibits EGFR tyrosine kinase, whereby the TACE inhibitor enhances the sensitivity of the cell to the EGFR tyrosine kinase inhibitor. Additionally, methods for treating cancer and methods for identifying TACE inhibitors is also provided.

Claims

1. A method for modulating proliferation of tumor cells, wherein the cells express TNF-α

Converting enzyme (TACE), the method comprising the steps of;

(a) contacting a tumor cell with a TACE inhibitor, and

(b) contacting the cell with a compound that inhibits epidermal growth factor receptor (EGFR) tyrosine kinase,

whereby the TACE inhibitor enhances the sensitivity of the cell to the compound of step (b).

2. The method of claim 1 wherein the cell is in a mammal.

3. The method of claim 2 wherein the mammal is a human.

4. The method of claim 1 wherein the TACE inhibitor is selected from the group consisting of antisense nucleic acid molecules, anti-TACE antibodies, siRNA oligonucleotides, soluble recombinant TACE protein fragments, small molecules, peptides and peptide mimetics.

5. The method of claim 1 wherein the TACE inhibitor is a small molecule.

6. The method of claim 5 wherein the small molecule is selected from the group consisting of (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′

-isobutyl-2′

-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), (2R,3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide (TMI-2), BMS-561392 (DPC-333), N—

(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine Amide (TNF-α

Protease Inhibitor-0), N—

(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine, 2-aminoethyl Amide (TNF-α

Protease Inhibitor-1), and N—

(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-t-butyl-alanyl-L-alanine, 2-aminoethyl Amide (TNF-α

Protease Inhibitor-2).

7. The method of claim 1 wherein the TACE inhibitor is a matrix metalloproteinase inhibitor.

8. The method of claim 1 wherein the TACE inhibitor is N—

(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-t-butyl-alanyl-L-alanine, 2-aminoethyl Amide and the compound that inhibits EGFR tyrosine kinase is AG 1478.

9. The method of claim 1 further comprising the step of contacting the cell with an anilinoquinazoline compound.

10. The method of claim 1 wherein the compound that inhibits EGFR tyrosine kinase is an antitumor therapeutic.

11. The method of claim 10, wherein the antitumor therapeutic is selected from the group consisting of:

Erlotinib, Gefitinib, AG1478, Canertinib (CI-1033), EKB-569, Lapatinib (GW572016), Erbitux (Cetuximab), ABX-EGF, EMD-72000, Thera CIM-h-R3, and HuMax-EGFR.

12. The method of claim 1 wherein proliferation of the tumor cells is inhibited.

13. A method of treating cancer comprising administering to a mammal in need thereof a therapeutically effective amount of a TACE inhibitor and a therapeutically effective amount of an EGFR tyrosine kinase inhibitor, whereby the TACE inhibitor enhances the sensitivity of a cell to the EGFR tyrosine kinase inhibitor.

14. The method of claim 13 wherein the EGFR tyrosine kinase inhibitor is an antitumor therapeutic.

15. The method of claim 14, wherein the antitumor therapeutic is selected from the group consisting of:

Erlotinib, Gleevec, Imatinib, Gefitinib, AG1478, CEP-1347, leflunomide, Semaxanib, Imidazo[1,2-a]pyrazin-8-ylamines, Canertinib (CI-1033), EKB-569, Lapatinib (GW572016), and monoclonal antibodies that target EGFR pathway including but not limited to, Erbitux (Cetuximab), ABX-EGF, EMD-72000, Thera CIM-h-R3, HuMax-EGFR, paclitaxel, cisplatin, carboplatin, chemotherapy, and radiation treatment.

16. The method of claim 13 wherein the TACE inhibitor is a small molecule.

17. The method of claim 16 wherein the small molecule is selected from the group consisting of (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′

-isobutyl-2′

-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), (2R,3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide (TMI-2), BMS-561392 (DPC-333), N—

(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine Amide (TNF-α

Protease Inhibitor-0), N—

(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine, 2-aminoethyl Amide (TNF-α

Protease Inhibitor-1), and N—

(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-t-butyl-alanyl-L-alanine, 2-aminoethyl Amide (TNF-α

Protease Inhibitor-2).

18. The method of claim 13 further comprising the step of administering an anilinoquinazoline compound.

19. A method of identifying a TACE inhibitor that sensitizes a tumor cell to an EGFR tyrosine kinase inhibitor, the method comprising the steps of:

(a) contacting a tumor cell with a compound suspected of being a TACE inhibitor,

(b) contacting the tumor cell with an EGFR tyrosine kinase inhibitor, and

(c) determining tumor cell proliferation,

whereby the compound that enhances the sensitivity of the tumor to the EGFR tyrosine kinase inhibitor is identified as a TACE inhibitor that sensitizes a tumor cell to an EGFR tyrosine kinase inhibitor.

20. The method of claim 19 wherein the cell is in a mammal.

21. The method of claim 20 wherein the mammal is a rodent.

22. The method of claim 19 wherein the compound suspected of being a TACE inhibitor is selected from the group consisting of antisense nucleic acid molecules, anti-TACE antibodies, siRNA oligonucleotides, soluble recombinant TACE protein fragments, small molecules, peptides and peptide mimetics.

23. The method of claim 19 wherein the compound suspected of being a TACE inhibitor is a small molecule.

24. The method of claim 23 wherein the small molecule is a matrix metalloproteinase inhibitor.

25. The method of claim 19 wherein the EGFR tyrosine kinase inhibitor is AG 1478.